Only 5–10% of MSS tumors co-occur with a BRAF mutation and the addition of ICIs to the targeted therapy is based on the increase of T cell infiltration caused by inhibiting BRAF with BRAF, MEK, and EGFR inhibitors. This evidence concerns the gene BRAF and Marinesco-Sjogren syndrome.